Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics and companion diagnostics. Its proprietary Drug Response Predictor (DRP®) platform identifies gene expression signatures to predict patient response to cancer drugs, enabling targeted treatment and streamlined clinical trials. The company’s lead asset, stenoparib, is a dual PARP and tankyrase inhibitor in development for advanced ovarian cancer, supported by DRP®-guided patient selection.
This description was generated via AI from an annual report. Updated about 1 year ago.